The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Thalassemia Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The 2022 Tandem Meetings | TCT highlights: long-term outcomes of beti-cel gene therapy for β-thalassemia
Agnieszka Czechowicz, MD, PhD, Stanford University, Stanford, CA, shares her highlights from a session on immune and gene therapy from the TCT meeting. Dr Czechowicz mentions the encouraging long-term results of betibeglogene autotemcel (beti-cel) gene therapy for patients with β-thalassemia showing improved outcomes with transfusion independence and low toxicity. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
